자궁근종에서 타목시펜의 수용체를 통한 기전

Abstract

Objectives: To investigate the distribution of ERα, ERβ, c-fos and c-jun in the uterine myoma and myometrium in oder to know how the tamoxifen cause the growth of myoma.

Methods: Myoma and myometrial tissue were obtained from the postmenopausal women treated with tamoxifen in the patients with breast cancer and in the prememopausal patients, who were undergoing myoma of uterus from 1998 through 2000. The expression of each gene was quantitated with quantitative RT-PCR.

Results: The expression of ERα was slightly increased in the myoma than the myometrium in the proliferative phase, and was slightly decreased in the myometrium than the myoma in the secretory phase. However it was not significant statistically. In the postmemopausal women treated with tamoxifen, ERα was expressed in all myoma and myometrial tissues and the expression was not statistically significant. The expression of ERβ was slightly increased in the myometrium than the leiomyoma in the proliferative and secretory phase, but it was not significant statistically. In the postmemopausal women treated with tamoxifen, the expression of ERβ was significantly increased in the myometrium than the leiomyoma. The expression of c-fos was significantly increased in the myometrium than the leiomyoma in the proliferative and secretory phase. In the postmemopausal women treated with tamoxifen, the expression of c-fos was slightly increased in the leiomyoma than the myometrium, however, it was not statistically significant.

Conclusion: Tamoxifen may cause the growth of leiomyoma by ERα with AP-1 pathway reducing the counteraction of ERβ to ERα.